KBio aims to create a new generation of biologics using its plant-based platform that has demonstrated the ability to create drug candidates at a fraction of the time and cost of conventional platforms. The Company is focused on developing novel product candidates in two core areas: 1) Antibody therapies for areas of high unmet need; and 2) Pandemic preparedness and response using its plant-based production system to create antibodies and vaccines in shorter timeframes than industry norms.
 
Formed in December 2021, KBio is a subsidiary of BAT with operations in the UK and U.S. 

KBio

Patrick Doyle

Travis Newton

Oscar Guzmán, M.D. CP

Matt Best

Frank Sutherland

Kurt Wong

The Leadership Team at KBio is responsible for guiding the strategic vision and direction of the company. Composed of the Chief Executive Officer and Principal Scientists, the team oversees the development and execution of innovative plant-based biologics. They ensure alignment with the company's goals of addressing high unmet medical needs through antibody therapies and enhancing pandemic preparedness with rapid antibody and vaccine production.

Leadership Team

About

Team members

Other teams at KBio

Science and Engineering